Noninvasive Evaluation of Liver Fibrosis Reverse Using Artificial Neural Network Model for Chronic Hepatitis B Patients

Table 2

Patient characteristics at 78 w between reverse and nonreverse groups.

	Reverse (n = 55)	Nonreverse (n = 86)	t/Z value
Gender, n (%)
Male	35 (63.6)	68 (79.1)	4.059	0.044
Female	20 (36.4)	18 (20.9)
Age
Mean ± SD	36.4 ± 10.0	36.5 ± 9.8	0.058	0.953
HBVDNA log10 (IU/ml)
Median (P25, P75)	1.3 (1.3, 1.3)	1.3 (1.3, 1.5)	1.197	0.231
ALT (U/L)
Median (P25, P75)	22 (16, 32)	28 (19, 36)	1.988	0.048
AST (U/L)
Median (P25, P75)	21 (18, 27)	27 (21, 32)	3.060	0.003
PLT (E9/L)
Median (P25, P75)	182 (132, 211)	132 (104, 174)	3.478	<0.001
WBC (E9/L)
Mean ± SD	5.2 ± 1.4	4.2 ± 1.6	3.744	<0.001
ALB (g/L)
Mean ± SD	45.3 ± 3.8	44.8 ± 4.1	0.719	0.473
CHE (μmol/L)
Median (P25, P75)	7134.0 (9.5, 9371.0)	9.5 (7.4, 7244.0)	3.217	0.001
TBIL (μmol/L)
Mean ± SD	12.7 ± 5.7	13.6 ± 5.9	0.886	0.371
BUN (mmol/L)
Mean ± SD	4.4 ± 1.0	4.7 ± 1.2	1.502	0.136
Cr (μmol/L)
Mean ± SD	65.1 ± 13.5	69.4 ± 12.6	1.882	0.062
PT (s)
Mean ± SD	11.5 ± 0.9	11.5 ± 0.9	0.001	0.999
LSM (kPa)
Median (P25, P75)	5.8 (4.8, 7.5)	6.6 (5.4, 8.9)	2.024	0.043